Anika Therapeutics (ANIK) vs Lifecore Biomedical (LFCR)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Anika Therapeutics (ANIK) has outperformed Lifecore Biomedical (LFCR) over the past year, gaining 108.1% versus a loss of 6.4%. Over five years, LFCR leads with a -34.5% price change compared with -53.8% for ANIK. Anika Therapeutics is the larger company by market cap ($263.3 million vs $244.1 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ANIK | LFCR |
|---|---|---|
| Share price | $19.68 | $6.44 |
| Market cap | $263.31M | $244.11M |
| 1-day change | +2.31% | +0.16% |
| YTD return | +100.10% | -21.39% |
| 1-year return | +108.12% | -6.40% |
| 5-year return | -53.84% | -34.45% |
| Forward P/E | 20.71 | — |
| EPS (TTM) | $-0.23 | $-1.27 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $22.88 | $8.98 |
| 52-week low | $8.67 | $3.63 |
| Distance from 52-week high | -14.01% | -28.29% |
| Analyst consensus | strong_buy | hold |
| Avg. price target upside | +16.90% | -2.48% |
| Average volume | 99.71K | 294.61K |
| Shares outstanding | 13.38M | 37.91M |
| Employees | 235 | 382 |
| Sector | Health Care | Health Care |
| Industry | Medical/Dental Instruments | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- ANIK has outperformed LFCR by 114.5 percentage points over the past year.
About Anika Therapeutics
ANIK stock →Anika Therapeutics, Inc., a joint preservation company, focuses on early intervention orthopedics in the United States, Europe, and internationally. The company offers osteoarthritis (OA) pain management products and services, such as Monovisc and Orthovisc, which are single- and multi-injection, HA viscosupplement products indicated for pain relief from OA conditions, as well as Cingal, a non-opioid, single-injection OA pain management product; regenerative solutions, including an HA-based scaffold with bone and tendon fixation components and arthroscopic delivery instruments; Hyalofast, a resorbable scaffold used for single stage cartilage regeneration; and Tactoset injectable bone substitute, an HA-enhanced injectable bone repair therapy designed to treat insufficiency fractures and augment hardware fixation.
Health Care · Medical/Dental Instruments · 235 employees
About Lifecore Biomedical
LFCR stock →Lifecore Biomedical, Inc., together with its subsidiaries, operates as an integrated contract development and manufacturing organization that serves customers in the United States, Belgium, the Netherlands, and internationally. It provides services in the development, manufacture, aseptic fill, and finish of formulations and highly viscous sterile injectable pharmaceutical drug or medical device products in syringes, vials, and cartridges in various modalities.
Health Care · Biotechnology: Pharmaceutical Preparations · 382 employees
ANIK vs LFCR FAQ
Which is bigger, Anika Therapeutics or Lifecore Biomedical?
Anika Therapeutics (ANIK) is larger, with a market capitalization of $263.31M compared with $244.11M for Lifecore Biomedical (LFCR).
Which stock has performed better over the past year, ANIK or LFCR?
ANIK returned +108.12% over the past 12 months, compared with -6.40% for LFCR (price return, excluding dividends). Past performance does not predict future results.
Are Anika Therapeutics and Lifecore Biomedical in the same industry?
Both are in the Health Care sector, but in different industries: Medical/Dental Instruments for Anika Therapeutics and Biotechnology: Pharmaceutical Preparations for Lifecore Biomedical.